# Abdominal Aortic Aneurysm Repair Devices Market

> Abdominal Aortic Aneurysm Repair Device Market Research Report By Material (Polytetrafluoroethylene (PTFE), Polyester, Polyethylene Terephthalate (PET), Polypropylene, Bioabsorbable materials), By Type (Endovascular Aortic Repair (EVAR), Open Surgical Repair, Hybrid Repair), By Fixation Method (Suprarenal fixation, Infrarenal fixation, Fenestrated fixation), By Endovascular Device (Balloon-expandable Stent-Grafts, Self-Expanding Stent-Grafts, Branched Stent-Grafts, Fenestrated Stent-Grafts, Covered Stents) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) Forecast to 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 5.45%
- **2025:** USD 2.65 Billion
- **2035:** USD 4.50 Billion
- **Key Players:** Medtronic plc, W. L. Gore & Associates, Cook Medical, Terumo Corporation (Terumo Aortic), Endologix LLC, Artivion Inc., MicroPort Endovastec, Lifetech Scientific

**Report ID:** MRFR/MED/7357-HCR · **Pages:** 128 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** November 03, 2026

**URL:** https://www.marketresearchfuture.com/reports/abdominal-aortic-aneurysm-repair-devices-market-8829

---

## Market Summary

## Abdominal Aortic Aneurysm Repair Devices Market Summary

The [abdominal aortic aneurysm](https://www.marketresearchfuture.com/reports/abdominal-aortic-aneurysm-market-30142) repair devices market was valued at USD 2.65 billion in 2025 and is projected to reach USD 2.79 billion in 2026 before climbing to USD 4.50 billion by 2035, a CAGR of 5.45% across 2026–2035. Two catalysts anchor that trajectory. Population screening keeps feeding the treatment funnel, led by the U.S. Preventive Services Task Force recommendation of one-time ultrasound screening for men aged 65–75 who have ever smoked [2]. Labeling is also widening: in October 2025, the FDA approved Medtronic's Endurant label for ruptured aneurysms, removing a long-standing treatment warning [11].

The second narrative pertains to technology substitution. The traditional method of open surgical repair, which involved the use of a sutured Dacron or ePTFE tube graft, has been replaced by catheter-delivered endografts that are inserted through the femoral arteries. The evidence base is mature: the EVAR-1 trial demonstrated a 30-day mortality rate of 1.8% for endovascular repair compared to 4.3% for open surgery [4]. The frontier has now advanced to the visceral segment, where W. L. Gore obtained FDA approval in January 2024 for the first off-the-shelf thoracoabdominal branch device in the United States [10].

The abdominal aortic aneurysm repair devices market is dominated by North America, with a 41.2% share in 2025. This market is bolstered by Medicare screening coverage and a dense vascular surgery capacity. The Asia-Pacific region is experiencing the highest rate of growth, with a compound annual growth rate (CAGR) of 7.3%. This growth is being fueled by the aging demographics of Japan and the expansion of domestic production in China. A thorough clinical-trial infrastructure and organized national screening are the foundations of Europe's second-place ranking. In the coming decade, the selection of a device will be more dependent on the platform's ability to manage complex necks, outpatient workflows, and long-term surveillance, rather than solely on sealing.

## Key Report Takeaways

### • By Product Type

- Endografts account for 54.3% of the abdominal aortic aneurysm repair devices market in 2025, reflecting their role as the core implant in every endovascular case.
- Delivery Systems are expanding at a 6.9% CAGR as low-profile, steerable catheters shorten procedure times.

### • By Procedure Type

- Endovascular Aneurysm Repair (EVAR) represents 74.4% of the abdominal aortic aneurysm repair devices market, making it the dominant treatment pathway.
- Open Surgical Repair is growing at a 3.2% CAGR, sustained by younger patients and hostile-neck anatomy.

### • By End User

- Hospitals hold a 69.6% share, backed by [hybrid operating rooms](https://www.marketresearchfuture.com/reports/hybrid-operating-room-market-862) and multi-size graft inventories.
- Ambulatory Surgical Centers post the fastest end-user growth at a 7.5% CAGR as same-day EVAR protocols mature.

### • By Anatomy

- Infrarenal AAA accounts for 73.3% of treated cases, the anatomy for which most commercial devices are indicated
- Pararenal AAA is advancing at a 6.6% CAGR on the back of fenestrated and branched graft approvals

### • By Region

- North America leads with a 41.2% share in 2025
- Asia-Pacific is the fastest-growing region at a 7.3% CAGR
- Europe generated USD 0.74 billion in 2025

## Market Size and Forecast (2026–2035)

Historical values for the abdominal aortic aneurysm repair devices market over 2021–2024 were reconstructed from manufacturer segment disclosures, national procedure registries and hospital procurement data, then reconciled against device-level shipment estimates. The 2025 base year combines bottom-up procedure volumes with average selling prices by product type, validated through interviews with vascular surgeons, interventional radiologists and supply-chain managers. Forecasts for 2026–2035 apply scenario-weighted assumptions on screening uptake, EVAR penetration and complex-anatomy device adoption.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Ageing population and rising aneurysm prevalence | +1.2% | Global | Long-term (≥4 yr) | [1] |
| Organised screening programmes | +0.9% | North America, Europe | Medium-term (2–4 yr) | [2], [3] |
| Clinical evidence favouring endovascular repair | +1.0% | Global | Short-term (≤2 yr) | [4] |
| Fenestrated and branched device approvals | +0.8% | North America, Europe | Medium-term (2–4 yr) | [10], [13] |
| Low-profile delivery and wider anatomical indications | +0.6% | Global | Short-term (≤2 yr) | [20] |
| Endovascular labeling for ruptured aneurysms | +0.4% | North America | Short-term (≤2 yr) | [9], [11] |
| Rapid ageing in Japan and wider Asia-Pacific | +0.5% | Asia-Pacific | Long-term (≥4 yr) | [18] |

### Ageing Population and Rising Aneurysm Prevalence

Age is the strongest non-modifiable risk factor for aortic aneurysm, and the global population is getting older fast. United Nations projections show the share of people aged 65 and above rising from 10% in 2022 to 16% by 2050 [1]. Aortic aneurysm already causes roughly 170,000 deaths worldwide each year [19]. Every additional cohort reaching its late sixties enlarges the pool of patients crossing the 5.5 cm intervention threshold recommended in U.S. guidelines [7], which sustains baseline procedure growth independent of any single technology cycle.

### Organised Screening Programmes

Screening converts silent disease into scheduled, elective procedures that favour device-based repair. The USPSTF grants a B recommendation for one-time ultrasound screening of men aged 65–75 who have ever smoked [2], and Medicare covers it in the Welcome to Medicare visit. England's national programme invites around 300,000 men each year in the year they turn 65 [3]. Elective cases detected this way are typically anatomically suitable for standard endografts, which lifts procedure volumes predictably.

### Clinical Evidence Favouring Endovascular Repair

Randomised data still shape purchasing committees. EVAR-1 reported 30-day mortality of 1.8% after endovascular repair versus 4.3% after open surgery [4], and later registries confirmed shorter length of stay and faster return to daily activity. Medtronic's ENGAGE registry presented 10-year Endurant outcomes at the 2023 Charing Cross Symposium across 49 sites in 21 countries [12]. That long-horizon evidence has eased concerns among payers and surgeons who had questioned late durability.

### Fenestrated and Branched Device Approvals

Pararenal and thoracoabdominal aneurysms were historically reserved for open surgery or custom-made grafts with multi-week lead times. Gore's January 2024 FDA approval of the EXCLUDER Thoracoabdominal Branch Endoprosthesis created the first off-the-shelf branched option in the U.S. [10]. Cook Medical also received FDA clearance in 2023 to begin an investigational study of its Zenith Fenestrated+ graft [13]. Each complex case consumes multiple bridging stents, raising revenue per procedure well above a standard bifurcated repair.

### Low-Profile Delivery and Wider Anatomical Indications

Smaller sheaths and shorter neck requirements expand the treatable population. Endologix's Alto system carries an indication for aortic necks as short as 7 mm, among the broadest in the U.S. [20]. Lower profiles allow fully percutaneous access in more patients, avoiding femoral cutdowns and reducing wound complications. Hospitals report that percutaneous EVAR cuts operating time and supports next-day or same-day discharge, which strengthens the economic case for endovascular repair.

### Endovascular Labeling for Ruptured Aneurysms

Ruptured aneurysms carry mortality above 80% overall [9], and many centres already used endografts off-label in emergencies. In October 2025, the FDA approved new Endurant labeling that adds ruptured-aneurysm evidence and removes the treatment warning, using real-world data from the International Consortium of Vascular Registries [11]. The change gives emergency teams regulatory backing and encourages hospitals to stock ready-to-use emergency kits, adding incremental device demand.

### Rapid Ageing in Japan and Wider Asia-Pacific

The Asia-Pacific region represents a fast-growing adoption center due to extreme demographic shifts. According to official data from Japan's Cabinet Office, the proportion of the population aged 65 and older reached 29.1% in 2023, representing the highest elderly population ratio globally. While Japan maintains high procedure rates via a certified operator network, expanding clinical capacity in China, South Korea, and ASEAN nations expands market reach. Local manufacturers, including MicroPort Endovastec and Lifetech Scientific, provide cost-effective graft solutions that increase treatment accessibility in regional public healthcare systems.

## Restraints

## Restraints Impact Analysis

Restraint impacts are directional estimates of downward pressure on the forecast growth rate of the abdominal aortic aneurysm repair devices market. They are not additive and partially offset one another as health systems adapt purchasing and clinical protocols.

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Late durability concerns and reintervention rates | −0.7% | Global | Long-term (≥4 yr) | [5] |
| Lifelong imaging surveillance burden | −0.4% | Global | Medium-term (2–4 yr) | [6] |
| EU MDR certification cost and timelines | −0.5% | Europe | Medium-term (2–4 yr) | [15] |
| Restrictive elective-EVAR guidance in the UK | −0.3% | Europe | Short-term (≤2 yr) | [8] |
| Physician and facility reimbursement pressure | −0.4% | North America | Short-term (≤2 yr) | [16] |

### Late Durability Concerns and Reintervention Rates

Long-term EVAR-1 follow-up showed that the early survival advantage of endovascular repair narrows and then reverses after about eight years, largely because of late sac rupture and secondary procedures [5]. Reintervention for endoleak or migration remains common across device generations. This evidence keeps open repair in play for younger, fit patients and pushes buyers to demand durability data before switching platforms.

### Lifelong Imaging Surveillance Burden

Every endograft requires follow-up imaging to detect endoleak, migration and sac growth. The 2024 European Society for Vascular Surgery guidelines recommend risk-stratified surveillance rather than uniform annual CT [6], yet compliance remains uneven. Repeated contrast CT adds radiation exposure and cost, and loss to follow-up undermines outcomes, which some payers cite when questioning the total cost of endovascular repair.

### EU MDR Certification Cost and Timelines

The EU Medical Device Regulation requires fresh clinical evidence and notified-body review for Class III implants such as endografts. Regulation (EU) 2023/607 extended transition deadlines to December 2027 for the highest-risk devices [15], but certification costs remain high. Smaller suppliers have narrowed portfolios or delayed European launches, which limits choice for surgeons and slows the arrival of new sizes and configurations.

### Restrictive Elective-EVAR Guidance in the UK

NICE guideline NG156 took a cautious line on endovascular repair for unruptured infrarenal aneurysms, favouring open surgery where patients are fit enough [8]. Although clinical practice has not shifted wholesale, the guidance influences commissioning discussions and procurement in parts of the NHS. It also signals to other cost-conscious health systems that EVAR adoption is not automatic.

### Physician and Facility Reimbursement Pressure

The CMS calendar-year 2025 physician fee schedule cut the conversion factor by 2.83% [16], squeezing surgeon payments for aortic procedures. Hospitals face rising labour and device costs while DRG payments trail inflation, and group purchasing organisations press suppliers for lower prices. These pressures cap average selling prices for standard bifurcated grafts and steer growth toward premium complex-anatomy devices.

## Opportunities

## Abdominal Aortic Aneurysm Repair Devices Market Opportunities

### Off-the-Shelf Solutions for Pararenal Disease

Pararenal AAA is the fastest-growing anatomy segment, yet many patients still wait weeks for custom-made devices. Standardized fenestrated and branched platforms that can be stocked on the shelf would capture urgent and symptomatic cases. According to WHO cardiovascular disease data, cardiovascular conditions remain the leading global cause of death, accounting for approximately 19.8 million deaths annually, representing nearly 32% of all global deaths. Suppliers that pair these grafts with dedicated bridging stents, such as the Advanta V12 covered stent approved in Europe for bridging use in October 2025 [14], can sell complete procedure systems rather than single implants.

### Emerging Markets in Asia-Pacific and Latin America

Asia-Pacific leads regional growth, yet procedure penetration in India, ASEAN, and Brazil remains a fraction of Western levels. United Nations demographic data projects that the proportion of the population aged 60 years and over in the Asia-Pacific region will reach 25.9% by 2050, accelerating cardiovascular healthcare requirements across developing healthcare systems. Tiered portfolios with lower-cost bifurcated grafts, local manufacturing, and surgeon training partnerships can unlock public-hospital tenders. Domestic manufacturers in China have shown how regional production lowers price points [23], an approach multinationals can replicate through licensing or joint ventures.

### Outpatient EVAR and Bundled Procedure Kits

Ambulatory Surgical Centers are the fastest-growing end-user segment for endovascular repairs. WHO noncommunicable disease mortality surveillance indicates that over 75% of global cardiovascular deaths occur in low- and middle-income nations, highlighting an urgent global necessity for cost-efficient, streamlined surgical delivery models. Kits combining the graft, delivery system, vascular closure device, and sizing software under one code simplify inventory management and billing for lean outpatient sites. Vendors offering consignment stock and on-site clinical specialists can capture market share in suburban centers currently underserved by tertiary vascular programs.

### Registry Data and Outcome-Based Business Models

Real-world registry data now support regulatory decisions, as demonstrated by the Endurant ruptured-aneurysm labeling update [11]. World Health Organization statistics confirm that noncommunicable diseases account for roughly 75% of non-pandemic deaths worldwide, driving payers to demand verified long-term clinical performance metrics from medical device manufacturers. Manufacturers can monetize registry datasets through advanced surveillance software, analytics subscriptions for hospital quality teams, and outcome-linked risk-sharing contracts with third-party payers. These models effectively transform one-time implant sales into long-term, recurring service relationships.

### AI-Driven Planning and Sizing

Automated CT segmentation and sizing tools reduce planning time and lower the risk of graft-anatomy mismatch, a leading cause of endoleak. Bundling planning software with device purchases creates switching costs and gives suppliers visibility into case pipelines. Smaller hospitals without dedicated aortic teams stand to gain most, which widens the addressable base.

## Future Outlook

## Abdominal Aortic Aneurysm Repair Devices Market Future Outlook

### AI-Assisted Planning and Image Guidance

Pre-operative planning is moving from manual centreline measurement to automated segmentation that proposes graft sizes in minutes. Intraoperative guidance is changing too: fibre-optic navigation can visualise catheters in 3D without continuous fluoroscopy [24]. Over the decade, these tools should cut radiation dose and contrast use, and make complex fenestrated cases feasible outside a handful of expert centres.

### Shift Toward Outpatient and Value-Based Care

Third-party payers and public health programs are increasingly incentivizing transitions to lower-cost outpatient facilities and outcome-focused payment models. As protocol optimizations refine same-day discharge criteria for EVAR patients, standard infrarenal repairs will progressively shift away from traditional inpatient stays. United Nations demographic data indicates that global life expectancy reached 73.3 years in 2024 and is projected to reach 77.4 years by 2054, putting long-term survival metrics at the center of healthcare evaluation. Consequently, device suppliers must prove high reintervention-free survival rates rather than initial technical placement success to secure value-based institutional contracts.

### Endovascular Expansion into Complex Aortic Anatomy

The next growth leg for the abdominal aortic aneurysm repair devices market lies above the renal arteries. Off-the-shelf branched devices [10] and investigational fenestrated platforms [13] point toward endovascular treatment of pararenal and thoracoabdominal disease as a mainstream option. The 2024 ESVS guidelines already recognise complex endovascular repair in experienced centres [6], which should accelerate training and adoption through the early 2030s.

### Materials, Sustainability and Supply-Chain Resilience

Abdominal endograft structural fabrics rely heavily on expanded polytetrafluoroethylene (ePTFE) and woven polyester. Regulatory scrutiny surrounding fluoropolymer supply chains—such as the European Chemicals Agency (ECHA) universal restriction proposal covering over 10,000 per- and polyfluoroalkyl substances (PFAS)—has raised long-term industrial compliance requirements. While specialized medical implants may secure specific regulatory derogations under EU REACH frameworks, manufacturers are proactively qualifying alternative polymer sources. Furthermore, hospital procurement departments are increasingly applying sustainability scoring metrics, requiring suppliers to transition to eco-friendly packaging and reprocessable procedural accessory kits.

## Segment Insights

## Abdominal Aortic Aneurysm Repair Devices Market Segmentation

### By Product Type

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Endografts | 54.3% share | Core implant in every endovascular repair |
| Delivery Systems | 6.9% CAGR | Demand for low-profile, steerable catheters |
| Ancillary Devices | USD 0.42 Billion | Balloons, snares, coils and closure devices used per case |
| Others | 6.5% share | Accessories and sizing tools |

Within the abdominal aortic aneurysm repair devices market, Endografts form the revenue core because every endovascular repair requires a main body and iliac limbs. Delivery Systems are growing faster as surgeons favour finer profiles, better torque and accurate positioning that shorten fluoroscopy time. Ancillary Devices, including balloons, snares and embolisation coils, provide steady demand tied to procedure volume, while Others cover sizing and accessory products.

### By Procedure Type

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Endovascular Aneurysm Repair (EVAR) | 74.4% share | Lower perioperative mortality and shorter recovery |
| Open Surgical Repair | 3.2% CAGR | Younger patients and anatomy unsuitable for endografts |

Endovascular Aneurysm Repair (EVAR) leads the abdominal aortic aneurysm repair devices market by procedure, reflecting its survival and recovery advantages for patients over 70. Each EVAR uses a premium graft kit plus imaging and closure accessories, which raises revenue per case, and it is also the faster-growing procedure. Open Surgical Repair grows slowly but remains essential for younger patients and short or angulated necks, with complex open cases increasingly concentrated in regional hubs.

### By End User

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Hospitals | 69.6% share | Hybrid operating rooms and critical care support |
| Ambulatory Surgical Centers | 7.5% CAGR | Same-day EVAR protocols and lower cost per case |
| Others | USD 0.24 Billion | Specialty vascular clinics and academic institutes |

Hospitals dominate the abdominal aortic aneurysm repair devices market by end user, thanks to hybrid theatres, critical care backup and large multi-size graft inventories. Ambulatory Surgical Centers are the fastest-growing setting as payers favour lower-cost venues for standard infrarenal repairs. Complex pararenal cases still flow to tertiary hospitals equipped with advanced imaging, so vendors need portfolios that serve both settings.

### By Anatomy

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Infrarenal AAA | 73.3% share | Favourable anatomy and mature device ecosystem |
| Pararenal AAA | 6.6% CAGR | Fenestrated and branched graft approvals |

Infrarenal AAA represents the largest anatomical segment of the abdominal aortic aneurysm repair devices market, since most commercial endografts are designed for necks below the renal arteries. Growth in this segment has steadied as the device ecosystem matures. Pararenal AAA is expanding faster because fenestrated and branched grafts now preserve visceral blood flow, and each case uses additional bridging stents that lift average procedure value.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 41.2% share | Ruptured-aneurysm labeling, branched devices, outpatient EVAR |
| Europe | USD 0.74 Billion | National screening, MDR-compliant portfolios, custom fenestrated grafts |
| Asia-Pacific | 7.3% CAGR | Ageing demographics, domestic manufacturing, operator training |
| South America | 4.6% share | Public-hospital tenders, private hospital networks |
| Middle East & Africa | USD 0.11 Billion | Tertiary cardiovascular centres, medical tourism |
| Total | USD 2.65 Billion | — |

North America remains the anchor of the abdominal aortic aneurysm repair devices market, while Asia-Pacific delivers the fastest expansion as ageing populations meet growing vascular surgery capacity. Europe follows closely behind North America, with screening maturity offset by regulatory friction.

### North America

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| US | 86.5% share of region | Medicare screening coverage and early access to new devices |
| Canada | USD 0.09 Billion | Provincial vascular programmes and reimbursement parity |
| Mexico | 6.8% CAGR | Private hospital expansion in major cities |

The United States dominates regional revenue, combining high screening rates under the USPSTF recommendation [2] with the earliest access to new platforms such as Gore's branched endoprosthesis [10]. The October 2025 Endurant labeling change [11] is expected to standardise emergency EVAR in trauma and tertiary centres. Canada's provincial programmes pursue reimbursement parity between open and endovascular repair, while Mexico's growth reflects private hospital investment in Monterrey, Guadalajara and Mexico City.

### Europe

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Germany | 23.8% share of region | High EVAR volumes and broad statutory insurance coverage |
| UK | USD 0.12 Billion | National screening programme for men aged 65 |
| France | 4.9% CAGR | Centralised vascular centres and complex aortic expertise |
| Italy | 11.6% share of region | Ageing population and regional tender procurement |
| Spain | USD 0.06 Billion | Public hospital modernisation |
| Nordic Countries | 5.2% CAGR | Population screening and registry-based follow-up |
| Russia | 4.1% share of region | Federal cardiovascular centre network |
| Rest of Europe | USD 0.12 Billion | Gradual EVAR adoption in Central and Eastern Europe |

Germany leads European demand through high procedure volumes and broad device availability. The UK benefits from its national screening programme [3], though NICE guidance tempers elective EVAR growth [8]. France and the Nordic Countries host many of the region's complex fenestrated programmes, supported by strong registries. Across the region, MDR certification [15] shapes which devices reach the market and when, favouring large suppliers with established clinical datasets.

### Asia-Pacific

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| China | 8.6% CAGR | Domestic manufacturers and tertiary hospital expansion |
| India | USD 0.05 Billion | Private cardiac hospital chains and rising diagnosis |
| Japan | 31.5% share of region | Highest share of elderly population and certified EVAR operators |
| South Korea | 7.8% share of region | National health insurance coverage of EVAR |
| ASEAN | 8.1% CAGR | Hospital investment in Thailand, Malaysia and Vietnam |
| Rest of Asia-Pacific | USD 0.06 Billion | Australia's mature vascular surgery practice |

Japan holds the largest regional share, driven by the world's oldest major population [18] and a structured operator certification system. China is the fastest-growing country in the regional abdominal aortic aneurysm repair devices market as domestic suppliers such as MicroPort Endovastec and Lifetech Scientific expand distribution beyond top-tier hospitals [23]. ASEAN markets are adding catheterisation and hybrid operating capacity, while India's demand concentrates in private cardiac hospital chains in metropolitan areas.

### South America

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Brazil | 58.4% share of region | Large private hospital networks and public-system tenders |
| Argentina | 5.6% CAGR | Specialist vascular centres in Buenos Aires |
| Rest of South America | USD 0.03 Billion | Gradual adoption in Chile, Colombia and Peru |

Brazil accounts for the majority of regional demand, with private hospital groups in São Paulo and Rio de Janeiro driving premium device uptake and the public health system purchasing through tenders. Argentina's growth relies on specialist centres despite currency volatility that complicates imports. Elsewhere, Chile and Colombia are expanding endovascular training, though limited reimbursement keeps open repair common outside major cities.

### Middle East & Africa

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 7.9% CAGR | Health sector transformation under Vision 2030 |
| UAE | 18.2% share of the region | Medical tourism and premium private hospitals |
| South Africa | USD 0.02 Billion | Private hospital groups and specialist surgeons |
| Egypt | 6.4% CAGR | Expanding university hospital capacity |
| Rest of MEA | 27.5% share of region | Gradual adoption across Gulf and North African markets |

Saudi Arabia's Vision 2030 health programme is funding new cardiovascular centres, making it the region's fastest-growing country. The UAE attracts complex aortic cases through medical tourism in Dubai and Abu Dhabi. South Africa's demand concentrates in private hospital groups, while Egypt's university hospitals are building endovascular capability. Device access across the region still depends heavily on distributor networks and imported inventory.

## Competitive Benchmarking

## Competitive Benchmarking

The abdominal aortic aneurysm repair devices market is moderately concentrated, with an estimated Herfindahl-Hirschman Index of around 1,800–2,000. The top five suppliers hold an estimated 75–82% of global revenue, led by Medtronic and W. L. Gore, with Cook Medical and Terumo forming a second tier. Regional Chinese producers and specialist firms compete on price and niche anatomy, keeping the long tail fragmented [21], [22].

| Company | Est. Revenue Share Range | Key Offerings for abdominal aortic aneurysm repair devices market | Strategic Positioning |
| --- | --- | --- | --- |
| Medtronic plc | ~28–33% | Endurant II/IIs stent graft system, Heli-FX EndoAnchor system | Broadest installed base; ruptured-aneurysm labeling leadership |
| W. L. Gore & Associates | ~22–27% | GORE EXCLUDER AAA, EXCLUDER Conformable, EXCLUDER TAMBE | Conformable and branched platforms for complex anatomy |
| Cook Medical | ~12–16% | Zenith Flex, Zenith Alpha, Zenith Fenestrated | Fenestrated pioneer with custom-made device expertise |
| Terumo Corporation (Terumo Aortic) | ~7–10% | TREO, Fenestrated Anaconda, surgical grafts | Combined endovascular and open-surgery portfolio |
| Endologix LLC | ~4–6% | Alto, AFX2 | Short-neck and anatomical-fixation niche |
| Artivion Inc. | ~3–5% | E-tegra, E-nside, surgical grafts | European branched and custom device focus |
| MicroPort Endovastec | ~2–4% | Aegis and Minos abdominal stent grafts | Price-competitive leader in China |
| Lifetech Scientific | ~1–3% | Ankura abdominal stent graft | Domestic Chinese supplier expanding exports |
| Getinge AB | ~1–3% | Advanta V12 covered stent, vascular grafts | Bridging stents for fenestrated repair |
| B. Braun Melsungen AG | ~1–2% | Vascular grafts for open repair | Open-surgery graft specialist |

## Recent News & Developments

## Recent News & Developments

- Medtronic (October 2025): FDA approved new Endurant labeling adding ruptured-aneurysm evidence and removing the rAAA treatment warning, giving emergency teams regulatory support for endovascular repair [11]
- Getinge (October 2025): The Advanta V12 covered stent received European approval for bridging indications, strengthening its role in fenestrated and branched procedures [14]
- W. L. Gore & Associates (January 2024): FDA approved the GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis, the first off-the-shelf branched device for complex aortic aneurysms in the U.S. [10]
- European Society for Vascular Surgery (January 2024): Published updated clinical practice guidelines on abdominal aorto-iliac aneurysms, refining surveillance and complex-repair recommendations [6]
- Cook Medical (2023): FDA approved an investigational device exemption study for the Zenith Fenestrated+ graft, extending endovascular treatment to aneurysms involving the visceral arteries [13]
- Medtronic (April 2023): Presented 10-year ENGAGE registry results for Endurant at the Charing Cross Symposium, reinforcing long-term durability evidence [12]
- European Union (March 2023): Regulation (EU) 2023/607 extended MDR transition periods, easing certification pressure on legacy endograft portfolios [15]

## Report Scope

| Parameter | Details |
| --- | --- |
| Market Scope | Covers endografts, delivery systems, ancillary devices and other products used in open surgical and endovascular repair of abdominal aortic aneurysms across hospitals, ambulatory surgical centers and other care settings. |
| Study Period | 2021–2035 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2035 |
| Market Size in 2025 | USD 2.65 Billion |
| Market Size in 2035 | USD 4.50 Billion |
| CAGR (2026–2035) | 5.45% |
| Fastest Growing Segments | Ambulatory Surgical Centers (7.5% CAGR); Delivery Systems (6.9% CAGR); Pararenal AAA (6.6% CAGR) |
| Regions Covered | North America, Europe, South America, Asia Pacific, Middle East and Africa and ROW |
| Companies Profiled | Medtronic plc, W. L. Gore & Associates, Cook Medical, Terumo Corporation, Endologix LLC, Artivion Inc., MicroPort Endovastec, Lifetech Scientific, Getinge AB, B. Braun Melsungen AG |
| Valuation Currency | USD Billion |
| Methodology | 350+ primary expert interviews; bottom-up market sizing; top-down validation; data triangulation; scenario-based forecasting; real-time project tracking |

## Frequently Asked Questions

**Q: How should hospital buyers compare suppliers in the abdominal aortic aneurysm repair devices market?**
A: Buyers should weigh sizing range and neck indications against inventory cost, since broad size matrices tie up capital. Consignment stock and on-site clinical support often decide tenders more than list price.

**Q: Which investment profiles attract capital in the abdominal aortic aneurysm repair devices market?**
A: Specialist investors in the abdominal aortic aneurysm repair devices market favour focused aortic platforms with differentiated indications. Endologix, for example, emerged from restructuring in 2020 under private ownership and kept investing in its Alto system [20].

**Q: What is the regulatory status of physician-modified endografts?**
A: Surgeons who modify commercial grafts on the back table operate outside the approved labeling. In the United States, structured programmes run these cases under investigational device exemptions, which limit routine commercial use.

**Q: How do EndoAnchors differ from conventional fixation in short-neck cases?**
A: EndoAnchors are helical screws that secure the graft directly to the aortic wall, mimicking a surgical suture. They serve as an adjunct to standard endografts rather than a replacement for fenestrated designs [21].

**Q: Why do hospitals face integration challenges with imaging systems in this abdominal aortic aneurysm repair devices market?**
A: Fusion imaging and planning software often come from different vendors than the graft itself. Hybrid rooms need compatible CT overlays and data links, which adds capital cost and IT validation work [24].

**Q: What operator requirements apply to endograft use in Japan?**
A: Japan requires physicians and facilities to meet certification standards set by the Japanese Committee for Stentgraft Management before using commercial endografts. This system protects outcomes but slows rollout to new hospitals [25].

**Q: How are suppliers addressing fluoropolymer supply risk?**
A: Manufacturers are qualifying second-source ePTFE and polyester yarns and testing alternative polymers against burst-strength standards. Dual sourcing raises validation costs but reduces exposure to potential restrictions [17].


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/abdominal-aortic-aneurysm-repair-devices-market-8829*